[Effective clinical use of cyclophosphamide in hematological malignancies].

Abstract

Cyclophosphamide (CPA) is the most widely used alkylating agent in the treatment of hematological malignancies. We review current clinical potential of high-dose CPA administration in this field. The efficacy of dose intensification of CPA in CHOP regimen for patients with aggressive lymphoma is being investigated in some clinical trials. High-dose CPA administration and G-CSF infusion effectively mobilize high levels of peripheral blood stem cell suitable for autografting. High-dose regimens of CPA alone or in combination with other agents also have been used to treat various hematological malignancies in conjunction with stem cell transplantation (SCT). A variety of adverse effects have been observed with the high-dose CPA used in preparative regimens for SCT. Hemorrhagic cystitis and cardiac toxicity are common and dose-limiting toxic effect of high-dose CPA administration.

• Authors: H Miyazaki, M Hirano
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 23 Issue 14 Pg. 1891-5 (Dec 1996) ISSN: 0385-0684 [Print] Japan
• PMID: 8978792 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Granulocyte Colony-Stimulating Factor
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Clinical Trials as Topic
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Drug Administration Schedule
• Granulocyte Colony-Stimulating Factor (administration & dosage)
• Hematologic Neoplasms (drug therapy)
• Humans
• Prednisone (administration & dosage)
• Vincristine (administration & dosage)